Introduction
Because hematologic pathology has no known spiritual predilection, BMT is indicated in a significant number of Jehovah's Witnesses (JWs) every year. These are seldom performed, usually because of physician apprehension about 'bloodless transplants.' Yet it is an obligation of the medical community to serve the needs of patients in a manner consistent with their beliefs. In areas such as cardiac surgery 1 and liver transplantation, 2 techniques developed out of necessity for JWs may have improved care for routine patients. There are several opportunities to minimize transplant-related morbidity and mortality in patients determined to undergo SCT without receiving plasma, RBCs or plts. Exploration of these approaches should facilitate the judicious use of transfusion in general and improve supportive care for all transplant patients. This study will recapitulate the relevant background on JWs and examine the existing data on bloodless transplantation. The supportive care measures that aid in blood conservation will be reviewed. Many of these techniques are also applicable to transplant patients without religious objection to transfusion.
Jehovah's Witnesses beliefs' and demographics
The JWs are members of a fundamentalist Christian religious group founded in 1872. Through aggressive evangelism and missionary work, they have emerged as a major worldwide religious group. According to the authorized website, there are 6.74 million practicing JW worldwide and 1.06 million members in the continental United States. 3 Central tenets of their beliefs include the conviction that Jesus Christ is the Son of God but separate from God and that the end of the world as prophesied by the Bible is already underway. They interpret the Holy Scriptures literally and consider them to be historically accurate.
The Bible explicitly forbids the eating of blood at several points throughout the Old Testament. It first appears in Genesis 9:3-5, during God's postdiluvian instructions to Noah:
Every moving thing that liveth shall be meat for you; even as the green herb have I given you all things. But flesh with the life thereof, which is the blood thereof, shall ye not eat. 4 This ban on eating blood is embellished in Mosaic law, most notably in Leviticus 17:10-14, wherein Israelites are reminded that 'the life of the flesh is in the blood' and that the punishment for eating blood is to be 'cut off from among his people.' The prohibition is reinforced in Acts 15:29 and Deuteronomy 12:16.
Although other religions, notably Judaism, attempt to follow Mosaic Law, the interpretation that the ban on eating blood extends to blood transfusion is unique to JWs. The JW transfusion ban was codified in 1945. Autologous transfusion was similarly forbidden, although it may be acceptable to some. In 1961, the punishment for accepting a blood transfusion was established as 'disfellowshipping' or 'shunning,' which often involved unconditional exclusion from the patient's community and support structure. The disfellowshipping requirement was repealed in 2000, but the spiritual and many practical repercussions of accepting transfusion are still in place. 5 The majority of JWs obey the no blood policy and carry 'medical directive cards,' which state 'I direct that no blood transfusions (whole blood, RBCs, WBCs, plts or blood plasma) be given to me under any circumstances, even if physicians deem such necessary to preserve my life or health.' 6 These cards are also designed to release physicians from liability caused by their refusal. A vocal minority of JWs openly accept blood and reject official Watchtower Society blood policy, 7 and a significant percentage will accept blood in specific medical situations. 8 Patients refusing transfusion should be informed that not all JWs think that refusal is obligatory. All competent patients should be queried about their specific preferences in a private environment removed from family, friends and coreligionists. Strict confidentiality must be assured should they accept transfusion. The JWs have established a Hospital Information Services and Liaison Committee for patients who request their assistance. Many patients wish to consult with this committee or with church elders before deciding on a particular treatment plan. Additional complexity arises when guardians refuse blood for their children; 9 this is beyond the scope of this review.
Applications to 'minor fractions' and stem cell transplantation
Blood can be extensively fractionated; serum alone contains over 1000 distinct gene products. 10 Neither the Old Testament authors nor the JW elders who instituted the ban on blood transfusion anticipated this complexity. The scriptural void on the use of blood fractions has been filled by evolving church doctrine. Current JW literature states that transfusion of whole blood or its four 'primary components' (RBCs, WBCs, plts and plasma) is forbidden. The dictum on 'minor fractions,' including albumin, immune globulin, clotting factors and stem cells, is more lenient. JW literature states that 'When it comes to fractions of any of the primary components, each Christian, after careful and prayerful meditation, must conscientiously decide for himself.' 11 Although these distinctions may seem artificial, caregivers should realize that most JWs are not merely submitting to an organizational mandate; they are earnestly striving to fulfill God's instructions. Because patients requiring transplant often have poor prognoses, the desire to abide by God's will is especially pertinent.
The act of apheresis and the collection of PBSCs are usually allowed, as it occurs in a system where the blood remains in continuity with the donor's circulation. But PBSCs and BM grafts are contaminated by leukocytes, RBCs and plasma. The latter two can potentially be removed by washing and replacement with albumin solution. Removal of leukocytes would require positive selection for CD34 þ cells, which is impractical and deviates from standard care. 12 Recipients should be made aware of these impurities; many will find them acceptable.
Because current doctrine forbids RBCs and plts but may allow BM or PBSCs as a matter of conscience, it creates a situation where SCT is often not offered to JW because of physician concerns for toxicity rather than patient refusal. Yet incremental progress is making 'bloodless' transplants tenable. Although transplant complexity and morbidity are increased, there are situations where the risk-benefit analysis in a given JW patient strongly favors transplantation. Patient selection, timing of transplant and supportive measures will all require adjustment.
Treatment of hematologic malignancies in Jehovah's Witnesses
With proper supportive care and regimen selection, patients receiving chemotherapy for Hodgkin or non-Hodgkin lymphoma can commonly avoid transfusion during first line and salvage chemotherapy. It is rare, however, for a transfusion-naive patient with acute leukemia to make it to transplant. Although children and adults with ALL or acute promyelocytic leukemia who refuse blood can achieve remission with modest success, patients with AML frequently die of anemia or bleeding during induction. This literature has been recently reviewed. 13 The most common indication for SCT is for multiple myeloma followed by non-Hodgkin lymphoma, AML, Hodgkin lymphoma and ALL. For routine myeloma patients, the proliferation of treatment options and the debatable merit of early autografting make transplant a less appealing option in light of the increased morbidity associated with a bloodless procedure. However, patients with relapsed lymphoma have few good non-transplant options and a high chance of cure with transplant. Informed consent of patients refusing transfusion involves an explicit discussion of the severe symptoms, multiple complications and mortality caused by uncorrectable anemia and thrombocytopenia.
14 A detailed list of acceptable products should be determined in writing well in advance of an emergency.
Autologous transplantation in Jehovah's Witnesses
The first case reports of high-dose chemotherapy followed by autologous stem cell rescue in a JW refusing blood were published in 1997. 15, 16 Since then, there has been a growing body of literature demonstrating the feasibility of autologous transplantation without transfusion (see Table 1 ). The two largest series reported a transplant mortality of below 10%. Ford and co-workers 20 at the Center for Bloodless Medicine and Surgery at Pennsylvania Hospital have performed the largest number of bloodless transplants and published their findings. The most illustrative series, reported by Ballen et al., 19 describes the outcomes of 26 patients undergoing Auto-SCT without the use of blood products. In this study, stem cells were mobilized using either G-CSF alone or a cocktail of G-CSF, EPO and IL-11. Patients received standard conditioning regimens for their disease, such as high-dose CY, BCNU and etoposide for lymphoma. Patients were administered i.v. iron, EPO, G-CSF and e-aminocaproic acid (Amicar) after stem cell infusion. The median platelet nadir was 6 Â 10 9 /l; the median Hb decrease was 4.7 g per 100 ml. One death was attributed to intracranial bleeding in a medulloblastoma patient who had a platelet count of 2 Â 10 9 /l; patients with intracranial malignancies were thereafter excluded. Another patient survived a major gastrointestinal bleed; there were three other minor bleeding complications. One patient died from complications of anemia on day þ 15 with Hb of 2.0 g per 100 ml; the study was again amended to require a starting Hb of more than 11 g per 100 ml. Patients in this study tended to be young (median age 40 years) and had been carefully chosen. Although it is not clear whether an unselected patient population would fare as well, the literature does support the conclusion that autologous transplantation can be performed with 'acceptable' mortality in appropriate patients refusing blood.
Allo-SCT in Jehovah's Witnesses
The evidence supporting myeloablative allogeneic transplants is considerably more austere. Although case reports and a very small series indicate that it may be feasible in highly selected patients, there are little data to support a bloodless myeloablative transplant 17, 21 (see Table 1 ). The advent of reduced-intensity transplantation has created a more realistic option for patients requiring allogeneic transplant but refusing blood. Transfusion requirements for non-myeloablative or reduced-intensity transplants are sharply reduced over full-intensity transplants; a significant percentage of these can be accomplished without transfusion. 25 There are a few case reports outlining successful bloodless reduced-intensity transplants in JWs. 23 Cord blood transplantation without transfusion support has not been described in adults.
Platelet transfusion in stem cell transplantation
A systematic 2004 review examined the appropriate 'trigger' for platelet transfusion after chemotherapy or stem cell transplant. 26 The authors found no significant differences in mortality, remission rates, severe bleeding events or RBC transfusion requirements between a transfusion threshold of 20 or 10 Â 10 9 /l plts. A recent study of 106 patients eliminated prophylactic transfusion altogether in clinically stable autologous stem cell recipients. Therapeutic transfusion was given for bleeding only. Regimens containing total body irradiation (TBI), because of its association with mucositis, required twice as many platelet transfusions as non-TBI regimens. The authors conclude that depending on the underlying disease and conditioning used, between 34 and 47% of autologous transplants can be performed without any platelet transfusion and without any bleeding. 27 The appropriate use of antifibrinolytics and other supportive measures would substantially raise this percentage.
Patients receiving PBSCs consistently experience faster neutrophil and platelet engraftment than patients receiving BM. 28 The CD34 þ cell dose is also directly related to the rate of platelet recovery. 29 Infusion of more than 10 Â 10 6 CD34 þ cells/kg leads to the most rapid and reliable engraftment. 30 The dose of CD34 þ cells co-expressing CD110 (c-mpl, the TPO receptor) may be the most important determinant of platelet recovery. 31 As delayed platelet recovery will increase mortality, at least 5 Â 10 6
CD34
þ cells should be collected for transplantation in any patient refusing transfusion. Repeated collections or alternative mobilization strategies, such as those using AMD3100, may be required to attain this goal. 32 A retrospective multicenter study of 789 patients examined factors affecting platelet recovery after transplant. 33 Higher CD34 counts in the graft and higher platelet counts at the start of conditioning hastened the time to a platelet count of 420 Â 10 9 /l. Factors adversely affecting platelet recovery include prior local radiation therapy and fever. Thrombocytopenia at the beginning of transplant is The bloodless transplant JM Sloan and K Ballen associated with increased platelet transfusion requirements. 34 The platelet count at the time of stem cell collection also appears to influence sustained platelet engraftment. 35 Ruiz-Arguelles et al. in Mexico have attempted to simplify transplant procedures to decrease costs and widen the availability of these treatments. Their institution has compiled experience with conservative transfusion strategies for 59 autologous transplants and 73 non-myeloablative transplants. 36 Plts were transfused for platelet counts below 10 Â 10 9 /l, or for o20 Â 10 9 /l if there was bleeding. The autografted patients received a median of 2 U of plts, and 25% did not require platelet transfusion at all. The allografted individuals required plts in only 65% of cases, with a median of 1 U transfused.
Weissinger et al. provide even more data that reducedintensity allogeneic transplantation can be routinely accomplished without platelet transfusion. They report that when patients were given plts prophylactically for counts less than 20 Â 10 9 /l (in-patients) or 10 Â 10 9 /l (outpatients), 100% of patients undergoing conventional HLA-identical sibling transplant required platelet transfusion. When a non-myeloablative regimen of TBI and fludarabine was used, only 23% of patients required plts. The median number of platelet units transfused was reduced from 24 to 0. 25 
Thrombopoietic growth factors
When G-CSF is given after Allo-or Auto-SCT, it consistently shortens the neutropenic period. 37, 38 The data for platelet and erythroid growth factors are less definitive. IL-11 is a growth factor that increases platelet production. 39 Recombinant IL-11 (oprelvekin) is Food and Drug Administration (FDA) approved to prevent severe thrombocytopenia and reduce the need for platelet transfusion after non-myeloablative chemotherapy. However, a single randomized trial tested oprelvekin in breast cancer patients undergoing autologous stem cell transplant. 40 Platelet transfusions were not reduced in the oprelvekin group over placebo; the oprelvekin group had more adverse events. Trials with other thrombopoietic growth factors have been similarly unable to document benefit in the setting of SCT. [41] [42] [43] As higher platelet counts prior to transplant shortens the duration of severe thrombocytopenia, there could be some role for oprelvekin prior to stem cell collection or immediately prior to high-dose chemotherapy in thrombocytopenic individuals. This has not been rigorously evaluated. Other thrombopoietic growth factors have been developed and are proving effective in a variety of circumstances. 44 On the basis of its efficacy in immune thrombocytopenic purpura, the FDA will likely approve AMG 531, a thrombopoiesis-stimulating protein. This compound is currently being tested for chemotherapyinduced thrombocytopenia; positive findings, although encouraging, will not necessarily translate into decreased platelet transfusion requirements after autologous transplantation.
RBC transfusion in stem cell transplantation
Anemia is a significant cause of death in patients refusing blood products. Insight into the consequences of severe anemia comes from data on patients refusing transfusion and studies of isovolemic hemodilution in normal volunteers. Cognitive function and memory are usually affected at 6 g per 100 ml but can be partially corrected with supplemental oxygen. 45, 46 Electrocardiographic changes occurred in only 5% of normal volunteers at Hb of 5 g per 100 ml. 47 A 1988 case-control study of surgical patients refusing blood transfusion found a 61.5% mortality with preoperative Hb o6.0 g per 100 ml. 48 Deaths attributable to anemia usually do not occur until Hb reaches o5 g per 100 ml, although many patients are able to survive at levels below this. 49 There are little data to guide clinicians in the treatment of severely anemic patients. There are no clinically approved artificial oxygen carriers for use in the United States; some are available on a compassionate use basis. Case reports have used RBC substitutes during periods of severe anemia after transplant in JWs. 24 Hypothermia does not improve tolerance to anemia in animal models. 50 The use of hyperbaric oxygen 51 and neuromuscular paralysis 52 have been described in case reports, but these measures are unlikely to salvage many patients.
Fortunately, the life span of endogenous RBCs is sufficiently long that an adequate pre-transplant hematocrit can carry an appropriately supported patient safely through transplant in the absence of bleeding or other complications. This is well demonstrated in a study by Baron et al. 53 of patients undergoing tandem autologous transplants for multiple myeloma. The mean Hb at the start of the initial transplant was 9.5 g per 100 ml, and 10 out of 11 patients required RBC transfusion during the first transplant. Patients were then administered EPO between transplants so that the mean Hb prior to the second transplant was 12.5 g per 100 ml. With this elevated pre-transplant Hb, only 1 out of 11 patients required transfusion. Even in transfusable patients, a low pre-transplant Hb is a known risk factor for increased peri-transplant mortality. 54 A pre-transplant Hb of above 12 g per 100 ml should be obtained in patients refusing transfusion; EPO-stimulating agents (ESAs) and intravenous iron should be used aggressively during the pretransplant period to hasten response and minimize delay. Ruiz-Arguelles et al. 36 were able to avoid RBC transfusion in 33% of their autografted patients by transfusing only for symptomatic anemia.
The intensity of the conditioning regimen impacts the kinetics of erythropoietic recovery and the amount of RBCs transfused. 55 Reduced-intensity allogeneic transplantation is possible without RBC transfusion. Weissinger et al. 25 report that when RBCs were given for symptoms or for a hematocrit below 26%, only 63% of the 40 patients required RBC transfusion. Ruiz-Arguelles et al. 36 were able to avoid RBC transfusion in 45% of their allografted patients receiving non-myeloablative conditioning. Aggressive treatment of bleeding and optimal supportive care could substantially improve this percentage.
A number of factors impact RBC production and survival. Fever shortens RBC survival and increases both RBC and platelet transfusion requirements. Aggressive treatment of hyperthermia with acetaminophen is therefore warranted. Many antibiotics are also myelosuppressive, some (for example, linezolid) strikingly so. Levofloxacin appears to reduce the risk of fever during transplantation without affecting engraftment. 56 
Erythropoietic-stimulating agents
Three ESAs are commercially available in the United States. Procrit, Epogen and Aranesp contain albumin but are acceptable to many JWs. An albumin-free product, Eprex, is available outside the United States, but it has been associated with pure RBC aplasia due to anti-EPO Abs. 57 ESA use is critical in patients refusing transfusion, although one must acknowledge the unease regarding increased thromboembolic events and tumor progression on these agents. 58 The use of exogenous EPO after allogeneic stem cell transplant is well supported in the literature. 59 The data on the benefit of EPO after autologous BMT are conflicting. Randomized trials of ESAs started after transplants generally failed to show any benefit. 60, 61 Despite the lack of evidence, most authors continue to give EPO and i.v. iron to patients after autologous transplant in patients refusing transfusion. The addition of ESAs to G-CSF for the purpose of stem cell mobilization does not appear to affect the composition in the apheresis product, nor does it significantly affect hematologic recovery. 62 The major role for EPO in autologous transplantation is in raising the pre-transplant Hb. 63 This should ideally be started during salvage chemotherapy. Responses to EPO will be optimized by the administration of parenteral iron, even in patients without absolute iron deficiency. 64, 65 Because of the importance of a rapid, reliable response, most anemic patients should be given i.v. iron along with EPO. Oral iron is substantially less effective. 66 
Treatment and prevention of bleeding in thrombocytopenic patients refusing transfusion
Without the ability to replace lost RBCs, even minor persistent bleeding from sources such as mucositis, hemorrhoids or epistaxis is life threatening. Bleeding must be prevented whenever possible and treated promptly and aggressively. Saline nasal spray, stool softeners and proton pump inhibitors help prevent epistaxis and minimize gastrointestinal losses. Menses should be fully suppressed. The frequency and volume of phlebotomy must be rigorously minimized. 67, 68 Pediatric-size blood collection tubes should be used. 68 Avoiding TBI during the preparative regimen will help prevent bleeding from mucositis. Palifermin (recombinant human keratinocyte growth factor) has been shown to reduce the severity and duration of oral mucositis in patients after intensive chemotherapy and radiotherapy for hematologic cancers, 69 and should be considered in all patients refusing transfusion. Topical Amicar may also be used to reduce blood loss related to mucositis.
Prolongations of PT/PTT (prothrombin time/partial thromboplastin time) in patients refusing transfusion are dangerous and need to be promptly addressed. In the transplant setting, PT/PTT prolongation may be due to deficiency of clotting factors from liver dysfunction, from consumption of clotting factors (as in disseminated intravascular coagulation) or from poor nutrition and antibiotic use. The measurement of fibrinogen and specific factor levels can be useful. Patients should be fully replete with vitamin K prior to and during transplant. Although plasma is forbidden, many JW patients accepting stem cells will also accept clotting factor concentrates. These include cryoprecipitate (containing factors VIII, von Willebrand factor, fibrinogen and factor XIII), prothrombin complex concentrates (containing factors II, IX, X and variable amounts of VII) and activated concentrates (including, recombinant factor VIIa (NovoSeven) and FEIBA). Some authors advocate for daily cryoprecipitate even in the absence of hypofibrinogenemia, although this practice is not evidence-based. 20 When the PT or PTT are prolonged, the deficient factor(s) should be identified and replaced to the extent possible. The etiology underlying the factor deficiency must be corrected.
Antifibrinolytic agents have been used to minimize perioperative blood transfusion and are useful in SCT to minimize bleeding during profound thrombocytopenia. Although aprotinin has the most evidence supporting its use, it has recently been taken off the market, and it appears that Amicar and tranexamic acid are at least as effective as aprotinin. 70 The published case series have started Amicar when the platelet count was below 30 Â 10 9 /l; doses were adjusted upwards for bleeding 19, 20 (see Table 2 ). Although generally very safe, Amicar should be used with extreme caution for patients with urinary bleeding or disseminated intravascular coagulation; doses must be adjusted for renal insufficiency. Desmopressin increases plasma concentrations of factor VIII and von Willebrand factor; it also enhances platelet adhesion to the vessel wall. 71 It appears to be ineffective in reducing perioperative blood transfusion; 72 and it has not been well studied in severely thrombocytopenic patients. The case series of transplantation in JWs used i.v. desmopressin 0.3 mg/kg every 12 h for 36 h for bleeding despite maximal doses of Amicar. Patients receiving desmopressin should be monitored for hyponatremia and caution should be exercised with repeat dosing.
Recombinant activated factor VII binds to tissue factor at the site of vessel injury and generates small amounts of thrombin on the platelet surface. 73 Although it is licensed in the United States only for the treatment of bleeding in hemophilia A or B with inhibitors or factor VII deficiency, it is often used to control hemorrhage in a variety of other settings. These off-label uses are highly controversial. 74 Although it is felt by some to be effective in extremely thrombocytopenic individuals, 75 it was not helpful in a trial to treat bleeding after Auto-SCT. 76 Despite these reservations, factor VIIa is frequently used for persistent bleeding despite maximal antifibrinolytic therapy. The optimal dose has not been established; the approved dose for patients with acquired hemophilia is 90 mg/kg every 2-3 h until hemostasis is achieved. Higher doses have been advocated. 77 There is no role for prophylactic factor VIIa. Substitutes for platelet transfusion, including infusible platelet membranes, are being developed but are not yet available. 78 Specific strategies to decrease need for transfusion Table 2 makes specific recommendations for Auto-SCT in JWs refusing transfusion.
Conclusions
The refusal of RBCs, plts and plasma is not an absolute contraindication to autologous or reduced-intensity allogeneic transplantation. In some circumstances, the treatment of patients with religious objection to transfusion is not pragmatically different from patients refractory to platelet transfusion. The treatment of these challenging patients offers insight into the appropriate use of transfusion in routine patients. The elimination of automatic transfusion triggers, the benefits of optimizing pre-transplant hematocrit and the judicious use of fibrinolytics are measures directly applicable to patients without religious objection to transfusion. The challenge of providing SCTs for JWs will continue to be an engine of change and improvement for all transplant recipients. Table 2 Recommendations for reducing the need for transfusion during autologous stem cell transplant
Pre-transplant
Optimize pre-transplant hemoglobin using ESA (e.g., EPO 40 000 U, s.c., weekly) and i. 
